The Compass approach

At Compass, we take an unbiased approach to drug discovery by leveraging our proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through our StitchMabs™ and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability.

To date, we have drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.


We are targeting the immune synapse with a new generation of antibody therapeutics

Ana Anderson, PhD

F. Stephen Hodi, MD

Robert A. Kramer, PhD

Mark Smyth, PhD

Phil Ferneau, MBA, JD

Managing Director and Co-founder, Borealis Ventures

Carl L. Gordon, PhD, CFA

Chairman of the Board, and Founding Partner and Co-head of Global Private Equity, OrbiMed Advisors

Brett Kaplan, MD

Chief Financial Officer, Prevail Therapeutics

Thomas J. Schuetz, MD, PhD

Co-founder and Chief Executive Officer, Compass Therapeutics

Stephen Squinto, PhD

Venture Partner, OrbiMed Advisors

Julie Sunderland

Managing Partner and Co-founder, Biomatics Capital Partners

Miranda Toledano, MBA

Chief Operating Officer and Chief Financial Officer, TRIGR Therapeutics